Controversy

What fraction of published glioma-imaging AI has robust external, multi-scanner, prospective validation

Evidence grade: WEAK — Supported only by weak or preliminary evidence.

computed from the encoded evidence by the Atlas grading rule.

Position A

A growing minority of models report external validation and geographic transfer

Position B

Most claims rest on internal cross-validation or single-institution splits; systematic reviews of medical-imaging AI (e.g. head-CT CNN meta-review) find external validation rare, reporting-standard adherence poor, and glioma-specific systematic external-validation evidence even sparser

Clinical stakes

Governs whether any of this reaches deployment; core reproducibility problem

Open in the interactive atlas →

About this page

Curated and maintained by Resonant Labs. Reviewed by Claims are synthesized from the cited literature and graded per the Atlas methodology (about the Atlas). Last updated 2026-07-01.

This is an educational research resource from Resonant Labs, not clinical advice. Evidence grades and controversies are summarized from the literature and may change as the field evolves.